• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿司匹林诱发的呼吸系统疾病患者中与哮喘控制相关的因素。

Factors associated with asthma control in patients with aspirin-exacerbated respiratory disease.

作者信息

Bochenek Grazyna, Szafraniec Krystyna, Kuschill-Dziurda Joanna, Nizankowska-Mogilnicka Ewa

机构信息

Department of Internal Medicine, Jagiellonian University Medical College, Skawinska 8, 31-066 Krakow, Poland.

Department of Epidemiology and Population Studies, Faculty of Health Sciences, Jagiellonian University Medical College, Grzegorzecka 20, 31-531 Krakow, Poland.

出版信息

Respir Med. 2015 May;109(5):588-95. doi: 10.1016/j.rmed.2015.02.015. Epub 2015 Mar 10.

DOI:10.1016/j.rmed.2015.02.015
PMID:25820158
Abstract

BACKGROUND

Effective control of asthma is the primary goal of its treatment. Despite an improved understanding of asthma pathogenesis and accessibility of novel therapies, the rate of uncontrolled asthma remains high.

OBJECTIVE

To find potential factors associated with asthma control in patients with aspirin-exacerbated respiratory disease (AERD).

METHODS

Clinical data were collected from a specifically structured questionnaire. Demographics, a history of upper airway symptoms, asthma course, exacerbations expressed as emergency department (ED) visits/hospitalizations, and asthma treatment were considered. Spirometry, skin prick tests, total IgE concentration, and blood eosinophil count were evaluated. Asthma control was assessed through the Asthma Control Test (ACT).

RESULTS

Out of 201 AERD patients, 41 (20.4%), 69 (34.3%), and 91 (45.3%) had controlled, partially controlled, and uncontrolled asthma, respectively. A multivariate ordered logistic regression analysis revealed that hospitalizations for asthma in the previous 12 months (OR 2.88; 95%CI, 1.11-7.46), ED visits for asthma throughout its duration (OR 1.05; 95%CI, 1.004-1.10), and total IgE concentration (OR 1.28; 95%CI, 1.02-1.60) were positively associated with poor asthma control, whereas FEV1 values (OR 0.98; 95%CI, 0.96-0.99) and medical care at a referential specialty clinic (OR 0.50; 95%CI, 0.27-0.95) were positively associated with good asthma control.

CONCLUSIONS

The prevalence of uncontrolled asthma in AERD patients is high and similar to that observed in different asthmatic populations. Owing both to the specificity and complexity of the disease, AERD patients should stay under regular care of well experienced referential medical centers to ensure that this asthma phenotype is dealt with effectively.

摘要

背景

有效控制哮喘是其治疗的首要目标。尽管对哮喘发病机制的认识有所提高,且新型疗法也更容易获得,但哮喘控制不佳的比例仍然很高。

目的

寻找阿司匹林诱发的呼吸道疾病(AERD)患者中与哮喘控制相关的潜在因素。

方法

通过一份专门设计的问卷收集临床数据。考虑了人口统计学、上呼吸道症状史、哮喘病程、以急诊就诊/住院次数表示的病情加重情况以及哮喘治疗情况。评估了肺功能、皮肤点刺试验、总IgE浓度和血液嗜酸性粒细胞计数。通过哮喘控制测试(ACT)评估哮喘控制情况。

结果

在201例AERD患者中,分别有41例(20.4%)、69例(34.3%)和91例(45.3%)的哮喘得到控制、部分控制和未得到控制。多变量有序逻辑回归分析显示,过去12个月因哮喘住院(比值比2.88;95%置信区间,1.11 - 7.46)、哮喘病程中急诊就诊次数(比值比1.05;95%置信区间,1.004 - 1.10)和总IgE浓度(比值比1.28;95%置信区间,1.02 - 1.60)与哮喘控制不佳呈正相关,而第1秒用力呼气容积(FEV1)值(比值比0.98;95%置信区间,0.96 - 0.99)和在参考专科诊所接受的医疗护理(比值比0.50;95%置信区间,0.27 - 0.95)与哮喘良好控制呈正相关。

结论

AERD患者中哮喘控制不佳的患病率很高,与在不同哮喘人群中观察到的情况相似。由于该疾病的特殊性和复杂性,AERD患者应在经验丰富的参考医疗中心接受定期护理,以确保有效应对这种哮喘表型。

相似文献

1
Factors associated with asthma control in patients with aspirin-exacerbated respiratory disease.阿司匹林诱发的呼吸系统疾病患者中与哮喘控制相关的因素。
Respir Med. 2015 May;109(5):588-95. doi: 10.1016/j.rmed.2015.02.015. Epub 2015 Mar 10.
2
Aspirin or other nonsteroidal inflammatory agent exacerbated asthma.阿司匹林或其他非甾体类抗炎药可加重哮喘。
J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):653-7. doi: 10.1016/j.jaip.2014.09.009. Epub 2014 Nov 6.
3
Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis.通过潜在类别分析区分的阿司匹林加重性呼吸系统疾病的某些亚表型。
J Allergy Clin Immunol. 2014 Jan;133(1):98-103.e1-6. doi: 10.1016/j.jaci.2013.07.004. Epub 2013 Aug 27.
4
Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity.诱导痰内源性前列腺素在阿司匹林过敏哮喘患者的阿司匹林支气管激发试验中的变化。
Allergy. 2014 Nov;69(11):1550-9. doi: 10.1111/all.12512. Epub 2014 Sep 12.
5
Prevalence of aspirin-exacerbated respiratory disease in patients with asthma in Turkey: a cross-sectional survey.土耳其哮喘患者中阿司匹林诱发的呼吸道疾病患病率:一项横断面调查。
Allergol Immunopathol (Madr). 2012 Jul-Aug;40(4):225-30. doi: 10.1016/j.aller.2011.05.015. Epub 2011 Sep 1.
6
Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease phenotype: Topical NSAID and asthma control - A possible oversight link.非甾体抗炎药(NSAID)加重的呼吸道疾病表型:局部用NSAID与哮喘控制——一个可能被忽视的关联
Respir Med. 2016 Sep;118:1-3. doi: 10.1016/j.rmed.2016.07.004. Epub 2016 Jul 9.
7
Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.特异性环氧化酶-2抑制剂依托考昔在阿司匹林诱发的呼吸道疾病哮喘患者中的安全性。
Ann Allergy Asthma Immunol. 2006 Jul;97(1):105-9. doi: 10.1016/S1081-1206(10)61378-6.
8
Safety of parecoxib in asthmatic patients with aspirin-exacerbated respiratory disease.帕瑞昔布在伴有阿司匹林加重的呼吸道疾病的哮喘患者中的安全性。
Int Arch Allergy Immunol. 2011;156(2):221-3. doi: 10.1159/000322841. Epub 2011 May 19.
9
Clinical significance of immunoglobulin E responses to staphylococcal superantigens in patients with aspirin-exacerbated respiratory disease.免疫球蛋白 E 对葡萄球菌超抗原反应在阿司匹林加重的呼吸道疾病患者中的临床意义。
Int Arch Allergy Immunol. 2013;162(4):340-5. doi: 10.1159/000353976. Epub 2013 Oct 25.
10
Association analysis of tapasin polymorphisms with aspirin-exacerbated respiratory disease in asthmatics.伴蛋白聚糖多态性与哮喘患者阿司匹林加重性呼吸道疾病的相关性分析。
Pharmacogenet Genomics. 2013 Jul;23(7):341-8. doi: 10.1097/FPC.0b013e328361d4bb.

引用本文的文献

1
Updates on the Natural History and Clinical Characteristics of NSAID-ERD.非甾体抗炎药相关的内镜阴性消化性疾病的自然史和临床特征的最新研究进展。
J Allergy Clin Immunol Pract. 2024 Nov;12(11):2889-2896. doi: 10.1016/j.jaip.2024.07.013. Epub 2024 Jul 20.
2
[Expert consensus on the diagnosis and treatment of respiratory diseases exacerbated by nonsteroidal anti-inflammatory drugs (2024, Chengdu)].非甾体抗炎药诱发的呼吸系统疾病诊治专家共识(2024年,成都)
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024 Jun;38(6):453-462. doi: 10.13201/j.issn.2096-7993.2024.06.001.
3
Lung Function and Asthma Clinical Control in N-ERD Patients, Three-Year Follow-Up in the Context of Real-World Evidence.
非嗜酸性粒细胞性难治性哮喘患者的肺功能与哮喘临床控制:基于真实世界证据的三年随访
J Asthma Allergy. 2023 Sep 6;16:937-950. doi: 10.2147/JAA.S418802. eCollection 2023.
4
Endoscopic sinus surgery improves aspirin treatment response in aspirin-exacerbated respiratory disease patients.内镜鼻窦手术可改善阿司匹林加重呼吸道疾病患者对阿司匹林的治疗反应。
Int Forum Allergy Rhinol. 2019 Dec;9(12):1401-1408. doi: 10.1002/alr.22418. Epub 2019 Sep 30.
5
The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease.生物标志物在诊断阿司匹林加重性呼吸道疾病中的应用。
Respir Res. 2018 Oct 30;19(1):210. doi: 10.1186/s12931-018-0909-6.
6
-rs573790 Is Associated With Aspirin-Exacerbated Respiratory Disease: Replicative Study Using a Candidate Gene Strategy.-rs573790与阿司匹林诱发的呼吸道疾病相关:采用候选基因策略的重复研究。
Front Genet. 2018 Sep 11;9:363. doi: 10.3389/fgene.2018.00363. eCollection 2018.
7
Reply.回复。
J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1808-1809. doi: 10.1016/j.jaip.2017.08.018.
8
Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.慢性鼻-鼻窦炎伴鼻息肉、哮喘和阿司匹林加重性呼吸道疾病患者的临床特征。
J Allergy Clin Immunol Pract. 2017 Jul-Aug;5(4):1061-1070.e3. doi: 10.1016/j.jaip.2016.12.027. Epub 2017 Mar 9.
9
Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.阿司匹林加重性呼吸疾病作为慢性鼻-鼻窦炎的一种内型
Immunol Allergy Clin North Am. 2016 Nov;36(4):669-680. doi: 10.1016/j.iac.2016.06.004. Epub 2016 Sep 13.
10
Automated identification of an aspirin-exacerbated respiratory disease cohort.阿司匹林加重性呼吸系统疾病队列的自动识别。
J Allergy Clin Immunol. 2017 Mar;139(3):819-825.e6. doi: 10.1016/j.jaci.2016.05.048. Epub 2016 Jul 25.